Shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) saw unusually-high trading volume on Wednesday. 360,958 shares were traded during trading, an increase of 118% from the previous session’s volume of 165,532 shares. The stock last traded at $99.7770 and had previously closed at $97.36.
iShares U.S. Pharmaceuticals ETF Stock Performance
The business’s fifty day moving average is $102.61 and its 200-day moving average is $96.34. The firm has a market cap of $1.55 billion, a P/E ratio of 17.75 and a beta of 0.47.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of IHE. MinichMacGregor Wealth Management LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF during the 3rd quarter valued at approximately $32,098,000. Valley Wealth Managers Inc. acquired a new position in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter worth approximately $90,000. Cadent Capital Advisors LLC lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 1,298.7% in the 3rd quarter. Cadent Capital Advisors LLC now owns 35,010 shares of the company’s stock worth $3,519,000 after purchasing an additional 32,507 shares during the period. Congress Asset Management Co. bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter valued at $56,000. Finally, Tidal Investments LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at $3,716,000.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Articles
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
